{"success":true,"data":{"pressRelease":{"id":"133076","rtpr_id":"nGNXbp6b4K","ticker":"SPRY","exchange":"NASDAQ","all_tickers":["SPRY"],"title":"ARS Pharmaceuticals to Participate in Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-09-01T20:01:00.096Z","article_body":"SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc.\n(Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk\npatients and their caregivers to treat and prevent severe allergic reactions,\ntoday announced that Donn Casale, President and CEO, will participate in the\nfollowing September investor conferences.\n\nWells Fargo Healthcare Conference\n* 1x1 Investor Meetings: Wednesday, September 9, 2026\n* Location: Boston\nCantor Global Healthcare Conference\n* Fireside Chat: Friday, September 11, 2026, 8:35 a.m. ET\n* 1x1 Investor Meetings: Thursday, September 10, 2026\n* Location: New York\nTo access the live and archived webcast from the Cantor Global Healthcare\nConference, please visit the Events & Presentations page in the “Investors &\nMedia” section of the Company’s website. A replay will remain available\nfor 30 days following the event.\n\nAbout ARS Pharmaceuticals, Inc.\n\nARS Pharma is a biopharmaceutical company developing and commercializing\ntreatments that help at-risk patients and their caregivers treat and prevent\nsevere allergic reactions. The company is\ncommercializing neffy(®) (epinephrine nasal spray), the only needle-free\nepinephrine approved by the U.S. Food & Drug Administration and European\nMedicines Agency, for the emergency treatment of Type I allergic reactions,\nincluding anaphylaxis, in adults and children weighing 33 lbs. (15kg) or more.\nThe product is marketed as EURneffy(®) in the European Union and as\n优敏速(®) in China. Leveraging its intranasal technology, ARS Pharma is\nalso developing ARS-2, currently in a Phase 2b clinical trial, as a potential\nfirst treatment for acute flares of chronic spontaneous urticaria (CSU). For\nmore information, visit www.ars-pharma.com and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=DPJK47TxSJUteOtNRNweCJ-zOJfvkh6HWNclQaQPMIMNpQKjWKC2p7XFcd88jPVt1NtH4Bq2ssnz47Jg3Z082KkBdqPYrib1EW9mq2Hnwk-CDb1fCQt470x7j7fQJR7VHtOUEbu_3eCG8JWjf1B6xA==)\nand X\n(https://www.globenewswire.com/Tracker?data=vIJeLpqaGNCGBdKwgZ9D37yFZ8CV6V7TfaDWLhE8cIsnZEEVSVAWwRKRzoL4G2dPN8b2OhsqXck7Wg94rpJh0Q==).\n\nARS Investor Contact:\nMonique Allaire, THRUST\nmonique@thrustsc.com\n\nARS Media Contact:\nChristy Curran, Sam Brown Inc.\n615.414.8668\nchristycurran@sambrown.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8feeb9d1-ed0c-491a-988b-a2b54778e825)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbp6b4K","title":"ARS Pharmaceuticals to Participate in Upcoming Investor Conferences","author":"Globe Newswire","ticker":"SPRY","created":"2026-09-01T20:01:00.096Z","tickers":["SPRY"],"exchange":"NASDAQ","article_body":"SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc.\n(Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk\npatients and their caregivers to treat and prevent severe allergic reactions,\ntoday announced that Donn Casale, President and CEO, will participate in the\nfollowing September investor conferences.\n\nWells Fargo Healthcare Conference\n* 1x1 Investor Meetings: Wednesday, September 9, 2026\n* Location: Boston\nCantor Global Healthcare Conference\n* Fireside Chat: Friday, September 11, 2026, 8:35 a.m. ET\n* 1x1 Investor Meetings: Thursday, September 10, 2026\n* Location: New York\nTo access the live and archived webcast from the Cantor Global Healthcare\nConference, please visit the Events & Presentations page in the “Investors &\nMedia” section of the Company’s website. A replay will remain available\nfor 30 days following the event.\n\nAbout ARS Pharmaceuticals, Inc.\n\nARS Pharma is a biopharmaceutical company developing and commercializing\ntreatments that help at-risk patients and their caregivers treat and prevent\nsevere allergic reactions. The company is\ncommercializing neffy(®) (epinephrine nasal spray), the only needle-free\nepinephrine approved by the U.S. Food & Drug Administration and European\nMedicines Agency, for the emergency treatment of Type I allergic reactions,\nincluding anaphylaxis, in adults and children weighing 33 lbs. (15kg) or more.\nThe product is marketed as EURneffy(®) in the European Union and as\n优敏速(®) in China. Leveraging its intranasal technology, ARS Pharma is\nalso developing ARS-2, currently in a Phase 2b clinical trial, as a potential\nfirst treatment for acute flares of chronic spontaneous urticaria (CSU). For\nmore information, visit www.ars-pharma.com and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=DPJK47TxSJUteOtNRNweCJ-zOJfvkh6HWNclQaQPMIMNpQKjWKC2p7XFcd88jPVt1NtH4Bq2ssnz47Jg3Z082KkBdqPYrib1EW9mq2Hnwk-CDb1fCQt470x7j7fQJR7VHtOUEbu_3eCG8JWjf1B6xA==)\nand X\n(https://www.globenewswire.com/Tracker?data=vIJeLpqaGNCGBdKwgZ9D37yFZ8CV6V7TfaDWLhE8cIsnZEEVSVAWwRKRzoL4G2dPN8b2OhsqXck7Wg94rpJh0Q==).\n\nARS Investor Contact:\nMonique Allaire, THRUST\nmonique@thrustsc.com\n\nARS Media Contact:\nChristy Curran, Sam Brown Inc.\n615.414.8668\nchristycurran@sambrown.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8feeb9d1-ed0c-491a-988b-a2b54778e825)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-01T20:01:00.136317192Z","server_sent_at_ms":1788292860136},"received_at":"2026-09-01T20:01:00.222Z","source_url":null},"analysis":{"id":"121966","press_release_id":"133076","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"ARS Pharmaceuticals announced that President and CEO Donn Casale will participate in the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference in September.\n\nThe schedule includes 1x1 investor meetings in Boston on September 9 and a fireside chat in New York on September 11.\n\nLive and archived webcasts of the presentations will be accessible via the Investors & Media section of the company’s website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Standard IR roadshow update."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Donn Casale","role":"President and CEO"}],"products":["neffy","EURneffy","优敏速","ARS-2"],"companies":[{"name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Cantor","relationship":"conference organizer"},{"name":"THRUST","relationship":"investor contact"},{"name":"Sam Brown Inc.","relationship":"media contact"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of participation in investor conferences with no material financial or operational updates disclosed."},"tickerRelevance":{"others":[],"primary":"SPRY"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap","eventGravity":"routine_conference"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ARS Pharmaceuticals announced that President and CEO Donn Casale will participate in the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference in September.\n\nThe schedule includes 1x1 investor meetings in Boston on September 9 and a fireside chat in New York on September 11.\n\nLive and archived webcasts of the presentations will be accessible via the Investors & Media section of the company’s website.","key_figures":null,"named_entities":{"people":[{"name":"Donn Casale","role":"President and CEO"}],"products":["neffy","EURneffy","优敏速","ARS-2"],"companies":[{"name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Cantor","relationship":"conference organizer"},{"name":"THRUST","relationship":"investor contact"},{"name":"Sam Brown Inc.","relationship":"media contact"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T20:01:54.234Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small/mid-cap","eventGravity":"routine_conference"}},"durationMs":54001,"modelName":"glm-4.7"}}